FOLLOWUS
A summary and evaluation of current evidence for myocardial infarction with Chinese medicine
- Chinese Journal of Integrative Medicine Vol. 23, Issue 12, Pages: 948-955(2017)
- Affiliations：
1. Department of Chinese Medicine, People’s Hospital of the Inner Mongolia Autonomous Region,Hohhot,China
2. Department of Emergency, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin,China
3. Department of Clinical Pharmacology, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin,China
4. Department of Encephalopathy Rehabilitation, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin,China
5. Department of Integrated Traditional Chinese and Western Medicine, Metabolic Diseases Hospital of Tianjin Medical University,Tianjin,China
6. Department of Massage Pain, Dongzhimen Hospital, Beijing University of Chinese Medicine,Beijing,China
7. Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine,Beijing,China
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 81430098 and 81603495) and the National High Level Talents Special Support Plan of the Organization Department of the Central Committee (No. W02020052)
DOI：10.1007/s11655-017-2824-y
CLC：Published：2017，
Published Online：27 October 2017，
Scan for full text
Wang, Y., Xiao, L., Mu, W. et al. A summary and evaluation of current evidence for myocardial infarction with Chinese medicine., Chin. J. Integr. Med. 23, 948–955 (2017). https://doi.org/10.1007/s11655-017-2824-y
Yue Wang, Lu Xiao, Wei Mu, et al. A summary and evaluation of current evidence for myocardial infarction with Chinese medicine. [J]. Chinese Journal of Integrative Medicine 23(12):948-955(2017)
Wang, Y., Xiao, L., Mu, W. et al. A summary and evaluation of current evidence for myocardial infarction with Chinese medicine., Chin. J. Integr. Med. 23, 948–955 (2017). https://doi.org/10.1007/s11655-017-2824-y DOI：
Yue Wang, Lu Xiao, Wei Mu, et al. A summary and evaluation of current evidence for myocardial infarction with Chinese medicine. [J]. Chinese Journal of Integrative Medicine 23(12):948-955(2017) DOI： 10.1007/s11655-017-2824-y.
摘要
To provide evidence-based recommendations for clinical application and provoke thoughts for future researchers by conducting a comprehensive summary and evaluation of the current evidence profile for the role of Chinese medicine (CM) in treating myocardial infarction (MI). Online databases including PubMed
EMBase
Cochrane Library
Chinese National Knowledge Infrastructure (CNKI)
Chinese Biomedical Medicine (CBM)
VIP Journal Integration Platform
and Wanfang database were systematically searched for literatures on CM in treating MI. After screening
studies were categorized into 5 types
i.e. systematic review (SR)
randomized controlled trial (RCT)
observational study
case report and basic research. General information was abstracted
and the quality levels of these studies and their conclusions were summarized and assessed. A total of 452 studies including 10 SRs
123 RCTs
47 observational studies
28 case reports
and 244 basic researches were selected. Clinical studies centered primarily on herbal decoction and mostly were not rigorously performed. High-quality studies were predominantly on Chinese patent medicines (CPMs) such as Danshen Injection (丹参注射液)
Shenmai Injection (参麦注射液)
Shengmai Injection (生脉注射液) and Qishen Yiqi Dripping Pills (芪参益气滴丸). The most frequently observed pattern of drug combination was decoction plus injection. Results of SRs and clinical studies showed that CM may reduce mortality
decrease risk of complication
reduce myocardial injury
improve cardiac function and inhibit ventricular remodeling. Findings from basic researches also supported the positive role of CM in reducing infarct size and myocardial injury
promoting angiogenesis
preventing ventricular remodeling and improving cardiac function. According to the current evidence body
CM has proven effects in the prevention and treatment of MI. It is also found that the effects of CPMs vary with indications. For instance
Shenmai Injection has been found to be especially effective for reducing the incidence of acute clinical events
while CPMs with qi-nourishing and bloodcirculating properties have been proven to be effective in inhibiting ventricular remodeling. High quality evidence supports the use of CM injection for acute MI and CPM for secondary prevention. Reports on adverse events and other safety outcomes associated with CM for MI are scarce. Sufficient evidence supported the use of CM as an adjuvant to Western medicine for preventing and treating MI. The choice of drug use varies with disease stage and treatment objective. However
the quality of the evidence body remains to be enhanced.
Abstract
To provide evidence-based recommendations for clinical application and provoke thoughts for future researchers by conducting a comprehensive summary and evaluation of the current evidence profile for the role of Chinese medicine (CM) in treating myocardial infarction (MI). Online databases including PubMed
EMBase
Cochrane Library
Chinese National Knowledge Infrastructure (CNKI)
Chinese Biomedical Medicine (CBM)
VIP Journal Integration Platform
and Wanfang database were systematically searched for literatures on CM in treating MI. After screening
studies were categorized into 5 types
i.e. systematic review (SR)
randomized controlled trial (RCT)
observational study
case report and basic research. General information was abstracted
and the quality levels of these studies and their conclusions were summarized and assessed. A total of 452 studies including 10 SRs
123 RCTs
47 observational studies
28 case reports
and 244 basic researches were selected. Clinical studies centered primarily on herbal decoction and mostly were not rigorously performed. High-quality studies were predominantly on Chinese patent medicines (CPMs) such as Danshen Injection (丹参注射液)
Shenmai Injection (参麦注射液)
Shengmai Injection (生脉注射液) and Qishen Yiqi Dripping Pills (芪参益气滴丸). The most frequently observed pattern of drug combination was decoction plus injection. Results of SRs and clinical studies showed that CM may reduce mortality
decrease risk of complication
reduce myocardial injury
improve cardiac function and inhibit ventricular remodeling. Findings from basic researches also supported the positive role of CM in reducing infarct size and myocardial injury
promoting angiogenesis
preventing ventricular remodeling and improving cardiac function. According to the current evidence body
CM has proven effects in the prevention and treatment of MI. It is also found that the effects of CPMs vary with indications. For instance
Shenmai Injection has been found to be especially effective for reducing the incidence of acute clinical events
while CPMs with qi-nourishing and bloodcirculating properties have been proven to be effective in inhibiting ventricular remodeling. High quality evidence supports the use of CM injection for acute MI and CPM for secondary prevention. Reports on adverse events and other safety outcomes associated with CM for MI are scarce. Sufficient evidence supported the use of CM as an adjuvant to Western medicine for preventing and treating MI. The choice of drug use varies with disease stage and treatment objective. However
the quality of the evidence body remains to be enhanced.
关键词
Chinese Medicinemyocardial infarctionclinical evidence
Keywords
Chinese Medicinemyocardial infarctionclinical evidence
references
China Pharmacopoeia Committee. China Pharmacopeia. Beijing: China Medical Science Press;2010.
American Heart Association. Heart disease and stroke. Statisties-2004 update.
Liu HX, Wang SR, Lei Y, Zhao D, Shang JJ. Study on the treatment status of acute myocardial infarction with traditional Chinese medicine. Fuzhou: The 12th annual meeting of China science association, forum of the position and role of traditional Chinese medicine in public health event;2010:123–129.
Sackett DL, Straus SE, Rrichardson WS, eds. Evidence-based medicine. Edinburgh Scotland: Churchill Living-stone;1997:2–3.
Wang Y, Yu HL, Guo LP. Primary discussion of the keys on the modernization of Chinese medicine. World J Integr Tradit West Med (Chin) 2014;7:768–770.
Dong DM, Wang YS, Liu B. Using way of evidence-based medicine to solve practical problems in surgical work. Chin J Surg (Chin) 2005;43:1619–1620.
Li YP, ed. Evidence-based medicine. Beijing: Higher Education Press;2009:21–23.
Lin Q, Nong YB, Duan WH. Meta analysis of clinical research literature on Chinese materia medica for acute myocardial infarction. Chin J Tradit Chin Med (Chin) 2006;21:528–531.
Zheng L, Liu HX, Shang JJ. The meta analysis of mortality and the recanalization rate in adjuvant treatment of acute myocardial infarction by traditional Chinese medicine preparations. J Emerg Tradit Chin (Chin) 2007;16:859–862.
Gao ZY, Guo CY, Shi DZ, Chen KJ, Xu H, Wu TX. Effect of Shengmai Injection on the fatality rate of patients with acute myocardial infarction: a systematic review. Chin J Integr Tradit West Med (Chin) 2008;28:1069–1973.
Zhang JH, Shang HC, Zhang BL, Gao XM, Xiang YZ, Wang H, et al. Systematic review of randomized controlled trials on treatment of myocardial infarction with Yiqihuoxue Chinese patent medicine. Chin J Tradit Chin Med Phar (Chin) 2008;23:300–306.
Song QG, Du WX, Liu M, Liu CY, Zhu LP, Zhu MD, et al. The impact Meta analysis of Yiqihuoxue traditional Chinese medicine on ventricular remodeling after myocardial infarction. Liaoning J Tradit Chin Med (Chin) 2008;35:323–325.
Huang MS. Effect of Shenmai Injection on the mortality rate and complications of patients with acute myocardial infarction: a meta-analysis [dissertation]. Guangzhou: Southern Medical University; 2009.
Wu T, Ni J, Wei J. Danshen (Chinese medicinal herb) preparations for acute myocardial infarction. Cochrane Library 2009;1:1–30.
Zeng YJ, Wang J, Zhou YC, Huang MX. Effect of Shenmai Injection on mortality rate of patients with acute myocardial infarction: a systematic review. Mod J Integr Tradit Chin West Med (Chin) 2010;19:3555–3558.
Jiang GF, Jiang YD, Zhan T. A systematic review of Shengmai Injection in the treatment of post-acute myocardial infarction hypotension. Chin Gener Pract (Chin) 2011;14:2644–2648.
Zhang J, Zhang MZ, Guo LH, Wang L, Zhang J. The systematic review of Chinese medicine in treating acute myocardial infarction. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2011;9:513–515.
Shang HC. The clinical trial about secondary prevention of Qishen Yiqi Dripping Pills on myocardial infarction got the acceptance of the expert group. Tianjin J Tradit Chin Med (Chin) 2010;27:266.
Lu ZL. China study of two grade prevention of coronary heart disease (CCSPs) the Cooperative group of the effect of Xuezhikang regulating blood lipid in two grade prevention of coronary heart disease. Chin J Cardio (Chin) 2004;3(Suppl 2):81.
Lu GP. Application of Shenmai Injection on acute myocardial infarction complicated with heart failure. Pract J Cardiac Cerebr Pneumal Vascul Dis (Chin) 2001;9:139.
Li GP, Zheng XT, Wang HZ, Zhang H, Chen SZ, Lu CZ. Multicenter investigation of Compound Danshen Dripping Pills on short term clinical events in patient with ST elevation myocardial infarction undergoing primary PCI. Chin J Interv Cardiol (Chin) 2011;19:24–28.
Chai YS, Yang SZ, Wang K. Effect of Shengmai Decoction add Shenfu Decoction on left ventricular function in patients with angina pectoris after acute myocardial infarction. Clin Emerg Treat Integr Tradit Chin West Med (Chin) 1998;5:536–538.
Chen JD, Lin JM, Zhu ZD. Observation of curative effect of Yiqi Huoxue medicine on acute myocardial infarction. J Pract Med (Chin) 1992;8:45–46.
Chen SW, Wu SC, Xie KY. Clinical analysis of thrombolytic therapy with Chinese medicine combined with urokinase for acute myocardial infarction. Shenzhen J Integr Tradit Chin West Med (Chin) 2009;19:173–175.
Li YH, Guan MD, Li L, Wu SP, Shi M, Zhu WY. Effect of Shenmai Injection on hemorheology in patients with diabetes mellitus complicated with acute myocardial infarction. J Med Inform (Chin) 2004;14:86–88.
Lu GP. Clinical observation of Shenmai injection in the treatment of acute myocardial infarction complicated with heart failure. Pract J Cardiac Cerebr Pneumal Vascul Dis (Chin) 2001;9:139.
Sun YY, Guo MS, Tian JB, Guo WQ. Observation of curative effect of Xuesaitong Oral Liquid on acute myocardial infarction. Chin Arch Tradit Chin Med (Chin) 2007;25:1430–1432.
Zeng QY. Di'ao Xinxuekang Capsule in treatment of acute myocardial infarction. New Drugs Clin Rem (Chin) 1995;14:343–346.
Zhai ZD, Xing XD, Liu HR, Li JE. Clinical observation of ventricular remodeling in patients with myocardial infarction treated by heart relaxing tablets. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2008;6:1259–1260.
Zhang JJ, Li QH, Chen LX, Zhang YW, Li DY. Clinical research of treatment from liver on heart dysfunction after acute myocardial infarction. Hebei J Tradit Chin Med (Chin) 2009;31:816–818.
Zhou X, You WQ, Xiu H. Treatment on 50 cases of acute myocardial infarction complicated with cardiac insufficiency with Salvia miltiorrhiza and Astragalus Injection. Tradit Chin Med Inf (Chin) 1998;2:24–25.
Luo JY, Liu YJ. Clinical observation of ventricular remodeling after myocardial infarction in treatment of Xiongbi Granula (qi deficiency and phlegm and blood stasis type). Hebei J Tradit Chin Med (Chin) 2006;28:816–818.
Ma L, Lei Y, Wang SW, Yang DY, Lu ZZ, Chen R. Effects of Shenqi Oral Liquid on plasma potassium peptide and left ventricular remodeling in patients with chronic heart failure after myocardial infarction. J Tradit Chin Med (Chin) 2003;44:909–911.
Xue T, Zhang ML. High dose of Shengmai and Danshen Injection in treatment of 5 patients with acute myocardial infarction and cardiogenic shock. Shanxi J Tradit Chin Med (Chin) 1997;18:462.
Zhao GY. The traditional Chinese medicine treatment experience of 124 cases with acute myocardial infarction. Med J Chin PLA (Chin) 1980;5:159–161.
0
Views
0
Downloads
2
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
